靶向组蛋白去乙酰化酶6重编程产白细胞介素17的辅助性T细胞致病性并促进肝细胞癌免疫治疗
肝细胞癌常对免疫治疗耐药。本研究显示组蛋白去乙酰化酶6(HDAC6)依赖其脱乙酰酶活性抑制产白细胞介素17(IL-17)的辅助性T(TH17)细胞致病性及抗肿瘤免疫应答。过继转移HDAC6缺陷的TH17细胞通过升高IL-17A增强抗肿瘤细胞因子产生和CD8+ T细胞介导的抗肿瘤反应,从而阻碍肝细胞癌生长;HDAC6缺失的T细胞触发PD-1-PD-L1表达,与免疫检查点阻断剂产生强协同效应。机制上HDAC6结合并脱乙酰化胞质FoxO1的K242位点,调控TH17细胞致病性和抗肿瘤效应,该调控在鼠和人类TH17细胞中高度保守。
要点
- HDAC6依赖脱乙酰酶活性抑制TH17细胞致病性和抗肿瘤免疫应答。
- HDAC6缺陷TH17细胞通过升高IL-17A增强CD8+ T细胞抗肿瘤反应并阻碍肝细胞癌生长。
- 靶向胞质HDAC6-FoxO1轴可重编程TH17细胞致病性以促进肝细胞癌免疫治疗。
核心结论
- 靶向胞质HDAC6-FoxO1轴可重编程肝细胞癌中TH17细胞的致病性和抗肿瘤反应,并促进免疫治疗疗效。
研究设计与样本
- 研究采用HDAC6缺陷TH17细胞过继转移的肝细胞癌模型,并分析HDAC6对鼠和人类TH17细胞的调控机制。
主要发现
- 过继转移HDAC6缺陷TH17细胞通过升高IL-17A增强抗肿瘤细胞因子产生和CD8+ T细胞介导的抗肿瘤反应,从而阻碍肝细胞癌生长。
- HDAC6缺失T细胞触发PD-1-PD-L1表达,与免疫检查点阻断剂产生强协同效应使晚期肝细胞癌致敏,而阻断IL-17A部分抑制该效应。
- HDAC6结合并脱乙酰化胞质FoxO1的K242位点,该位点为其核转位和稳定所必需,进而抑制TH17细胞转录因子RoRγt。
临床怎么用
- 靶向HDAC6-FoxO1轴或联合IL-17A调控可能增强肝细胞癌对免疫检查点阻断剂的敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is often accompanied by resistance to immunotherapies despite the presence of tumor-infiltrating lymphocytes. We report that histone deacetylase 6 (HDAC6) represses interleukin-17 (IL-17)-producing helper T (TH 17) cell pathogenicity and the antitumor immune response, dependent on its deacetylase activity. APPROACH AND RESULTS: Adoptive transfer of HDAC6-deficient TH 17 cells impedes HCC growth, dependent on elevated IL-17A, by enhancing the production of antitumor cytokine and cluster of differentiation 8-positive (CD8+) T cell-mediated antitumor responses. Intriguingly, HDAC6-depleted T cells trigger programmed cell death protein 1 (PD-1)-PD-1 ligand 1 expression to achieve a strong synergistic effect to sensitize advanced HCC to an immune checkpoint blocker, while blockade of IL-17A partially suppresses it. Mechanistically, HDAC6 limits TH 17 pathogenicity and the antitumor effect through regulating forkhead box protein O1 (FoxO1). HDAC6 binds and deacetylates cytosolic FoxO1 at K242, which is required for its nuclear translocation and stabilization to repress retinoic acid-related orphan receptor gamma (RoRγt), the transcription factor of TH 17 cell. This regulation of HDAC6 for murine and human TH 17 cell is highly conserved. CONCLUSIONS: These results demonstrate that targeting the cytosolic HDAC6-FoxO1 axis reprograms the pathogenicity and antitumor response of TH 17 cells in HCC, with a pathogenicity-driven responsiveness to facilitate immunotherapies.
引用
- Qiu W, Wang B, Gao Y, et al. Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma. Hepatology. 2020. PMID: 31539182. doi:10.1002/hep.30960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。